Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T20:58:27.539Z.
Calculation as of: 2026-10-06T20:58:27.539Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 79d0a2820bd4cbdc8dee1371cb6304dc007cf4c401fb8f8a9623f82368031b99
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$1.81M
EBITDA Yield
N/A
TTM Avg
0.19%
3Y Avg
0.19%
5Y Avg
0.19%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TransCode Therapeutics, Inc. (RNAZ) | $1.88M | N/A | N/A | N/A | N/A |
| Autonomix Medical, Inc. (AMIX)vs › | $1.88M | N/A | N/A | N/A | N/A |
| Tenon Medical, Inc. (TNON)vs › | $1.84M | N/A | N/A | N/A | N/A |
| Beyond Air, Inc. (XAIR)vs › | $1.84M | N/A | N/A | N/A | N/A |
| Profusa, Inc. Common Stock (PFSA)vs › | $1.83M | N/A | N/A | N/A | N/A |
| Alaunos Therapeutics, Inc. (TCRT)vs › | $1.81M | N/A | 0.19% | 0.19% | 0.19% |
| GeoVax Labs, Inc. (GOVX)vs › | $2.13M | N/A | 0.00% | 0.00% | 0.00% |
| Silo Pharma, Inc. (SILO)vs › | $1.64M | N/A | N/A | N/A | N/A |
| Vivos Therapeutics, Inc. (VVOS)vs › | $2.14M | N/A | N/A | N/A | N/A |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.52M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
